Bionano Genomics Inc. (BNGO)

factsheet Factsheet
  • Market Capitalisation market-capitalisation-info $264 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-140 Mln

Bionano Genomics Inc. (BNGO) Share Price

$1.51

As on 28-Nov-2023 16:00 EST

up-down-arrow $-0.02-1.31%

  • Prev Close info

    $1.53

  • Day's Openinfo

    $1.52

  • Today's Highinfo

    $1.53

  • Today's Lowinfo

    $1.46

  • Today's Volumeinfo

    808,465

  • 52 Week rangeinfo

    $1.19 - 59.18

Please wait...

Bionano Genomics Inc. (BNGO) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Bionano Genomics (BNGO)
-89.66 19.84 -50.17 -93.20 -32.40 -53.05 --
S&P BSE Sensex*
10.91 5.65 4.09 6.94 15.19 13.27 12.49
#
-- -- -- -- -- -- --
As on 28-Nov-2023  |  *As on 01-Dec-2023  |  #As on
2022
2021
2020
2019
Bionano Genomics (BNGO)
-51.17 -2.92 148.39 -76.34
S&P BSE Sensex
4.44 21.99 15.75 14.38
S&P BSE Sensex
4.44 21.99 15.75 14.38

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Bionano Genomics Inc. (BNGO) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Bionano Genomics Inc. (BNGO)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Bionano Genomics Inc. (BNGO)

        Pres, CEO, Sec. & Director

        Dr. Robert Erik Holmlin M.B.A., Ph.D.

        Chief Operating Officer

        Mr. Mark Oldakowski

        Headquarters

        San Diego, CA

        FAQs for Bionano Genomics Inc. (BNGO)

        The total asset value of Bionano Genomics Inc. (BNGO) stood at $ 330 Mln as on 31-Mar-23

        The share price of Bionano Genomics Inc. (BNGO) is $1.51 (NASDAQ) as of 28-Nov-2023 16:00 EST. Bionano Genomics Inc. (BNGO) has given a return of -32.4% in the last 3 years.

        Bionano Genomics Inc. (BNGO) has a market capitalisation of $ 264 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Bionano Genomics Inc. (BNGO) is 2.23 times as on 02-Jun-2023, a -0.24% premium to its peers’ median range of 2.95 times.

        Since, TTM earnings of Bionano Genomics Inc. (BNGO) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Bionano Genomics Inc. (BNGO) and enter the required number of quantities and click on buy to purchase the shares of Bionano Genomics Inc. (BNGO).

        Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

        The CEO & director of Dr. Robert Erik Holmlin M.B.A., Ph.D.. is Bionano Genomics Inc. (BNGO), and CFO & Sr. VP is Mr. Mark Oldakowski.

        The promoters of Bionano Genomics Inc. (BNGO) have pledged 0% of the total equity as on Dec-22.

        Bionano Genomics Inc. (BNGO) Ratios
        Return on equity(%)
        -54.47
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Bionano Genomics Inc. (BNGO) was $-140 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $264.15 Mln
        • Revenue (TTM)revenue-information $29.52 Mln
        • Earnings (TTM) earning-information $-139.77 Mln
        • Cash date-information $95.81 Mln
        • Total Debt info $11.17 Mln
        • Insider's Holding 1.83%
        • Liquidity liquidity High
        • 52 Week range week-range $1.19 - 59.18
        • Shares outstanding share-outstanding 306,790,016
        • 7 Years Aggregate:

          CFO: $-328.85 Mln

          EBITDA: $-326.05 Mln

          Net Profit: $-336.71 Mln

        About The Company

        • IPO Date 21-Aug-2018
        • Pres, CEO, Sec. & Director Dr. Robert Erik Holmlin M.B.A., Ph.D.
        • Chief Operating Officer Mr. Mark Oldakowski
        • Listing key-listing NASDAQ: BNGO
        • Country United States
        • Headquarters headquarters San Diego, CA
        • Website website https://www.bionanogenomics.com
        • Business

          Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It...  offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon